Vivodyne’s Post

On October 16, Andrew Dunn of Endpoints News will moderate the panel “Insurgents vs. Incumbents — Approaches to AI at Tiny Startups and Big Pharmas” at Endpoints AI Day 2024. Our EVP of Research & Development, Alexandra Snyder, MD, will join Jakob Uszkoreit of Inceptive and Sean Bruich (he/him) of Amgen to explore how #AI is reshaping biopharma—from drug discovery to Phase III—and whether the future belongs to legacy drugmakers or new tech-driven startups. The future of AI in pharma is here. Don’t miss out. Learn more: https://lnkd.in/gF48qYZ9 #ProgrammingBiology | #GenerativeAI

#Article: What makes a great #biotech #startup? Every year, the Endpoints 11 awards try to answer that question. They’ve spent the last several months examining dozens of finalists, talking to investors and biotech veterans to get their opinions, and debating who was worthy of inclusion. What they have come up with for this year’s class is a representation of the biggest bets, most interesting science and technology, and strongest leadership teams in the industry. There are three AI startups flush with cash, with very different philosophies. A Chinese ADC company that has defied the current geopolitical trends. And intriguing work in immunology, obesity, RNA editing and more. THE 2024 ENDPOINTS 11 ◉ Lifordi Immunotherapeutics, Inc.- Delivering #potentsteroids directly to #immunecells ◉ Mirador Therapeutics - Applying #precisionmedicine to #immunedisease ◉ Formation Bio - A Silicon Valley-fueled #AI unicorn ◉ Xaira Therapeutics - Biotech’s largest AI bet with A-list backers ◉ MediLink Therapeutics - China startup helps power the #ADC renaissance ◉ Iambic Therapeutics - The ‘show-me’ era for AI ◉ Ascidian Therapeutics - Search-and-replace tech comes to #RNA ◉ Capstan Therapeutics - Trying to win the #invivoCART race ◉ Seaport Therapeutics - The Karuna team is back with another big #neuroscience bet ◉ Metsera -@Clive Meanwell wagers on #obesity after The Medicines Company success ◉ Cardurion Pharmaceuticals - A shot at one of #heartdisease’s ‘undruggable’ targets Read the full article by Endpoints News Drew Armstrong, and learn more about each company 👇🏼

Pricing, Politics and AI To Take Center Stage in 2024 The JP Morgan Healthcare Conference (JPM) reflects the current mood of the life sciences market, and while the tenor was certainly more positive than in 2023, this optimism is dampened by economic uncertainty. Communicating with BioSpace, Daniella Kranjac, founding partner at Dynamk Capital is cautiously optimistic, “There are still a few dark clouds on the horizon, but with therapeutic-enabling technologies, Healthtech and other areas, our experience tends to inform a softer landing.” Not surprisingly, geopolitical and macroeconomic themes continue to play major roles in the market. As interest rates are expected to fall in 2024, and the industry sees more successful public offerings, the potential is there for investment dollars to return to biopharma. https://lnkd.in/g4Zug2Um #aspenalert #biotech #bioprocess

Exciting developments for #innovation and Swiss #spinoffs. In 2023 ETH Zürich recorded more spin-offs than ever before, with 43 new spin-off companies! Key highlights include: ➡️More companies connected to AI ➡️Strong focus on biotech and pharma ➡️A rise in the count of female founders

Hello everyone! This week's video is a little longer, but there were many important industry activities worth highlighting. As I mentioned in the video, exciting news from WorldUpstart which launches the next U.S. Market Gateway Accelerator. That includes 11 startups, so well done everyone: CheckEye, Diagnoly, DragOnFlow Systems LTD, Figura Analytics Limited, Hip Impact Protection, MediSensonic, Preventx, QiiQ Healthcare, Rostra Therapeutics, Unlimited Robotics and Vivid Health. More information is in the comments below. Well done Ceroflo for raising a 6.4M EUR investment and Hologic, Inc. to receive #FDA clearance on Genius #Cervical AI algorithm. Medovate Limited and JEB Technologies Ltd have become part of the same group structure. Under this strategic integration, both companies will unify their strengths across the entire medical device development pipeline so excited to see further developments. Follow #MedTechwithIndre and see you next Thursday! #medtech #digitalinnovation #medicaldevice

🌟 Yes! We're setting global standards! 🌟 I'm beyond thrilled to announce that Innoplexus' patent has been spotlighted by the World Intellectual Property Organization – WIPO, as a prime example of patents in #GenAI in life sciences for drug discovery. For the uninitiated, World Intellectual Property Organization – WIPO is a global forum for intellectual property services, policy, information, and cooperation, playing a pivotal role in protecting and promoting innovation worldwide. Being recognized by the World Intellectual Property Organization – WIPO is truly an honor and especially when we see other examples quoted there coming from companies like Salesforce, Tata Consultancy Services, IBM, Hyundai Motor Company (현대자동차), ABB, Samsung Electronics, Microsoft and Boeing . Heartiest congratulations to the entire Innoplexus - a Partex Company team for continuously pushing boundaries and revolutionizing drug discovery and development with artificial intelligence. As I always say, intellectual property is our powerhouse in staying competitive and patenting our expertise is key. Together, we are driving groundbreaking advancements in AI-driven healthcare! 🚀 Let's celebrate this milestone and keep pushing forward! Thanks once again to a few of our top innovators Adarsh Jain, Abhijit Keskar, Vatsal Agarwal, Rohit Singh Yadav, Rohit Anurag, Gunjan Bhardwaj, Arpan Sheetal. #IP #WIPO #Innoplexus #GenerativeAI #lifeSciences #DrugDiscovery #intellectualproperty #patents

Just kicked off a 7-part journey into the fusion of biology and AI. It's a deep dive into how biology is evolving from a field of discovery to one of precise engineering. Gone are the days of stumbling upon breakthroughs like penicillin. Now, we're talking about crafting drugs on computers, testing their efficacy and safety digitally, decreasing the rate of failure, and drastically reducing cost. In this episode, Vijay Pande, from a16z walks us through these changes - from healthcare innovation, to doctors teaming up with AI co-pilots, to what's what's happening with biotech startups. It's a peek into a future where medicine and tech blend in ways we've only started to imagine. 🧬🖥️ This isn't just about solving big problems; it's about tackling challenges that matter deeply, that can truly change the world. We're standing at the threshold of an era where the brightest minds in tech and entrepreneurship are turning their attention to biology. Welcome to what could be the defining age of biology in the 21st century. Vijay Pande, PhD | Andreessen Horowitz | Software Engineering Daily https://lnkd.in/dUwceTh4

Biotech’s Dirty Secret: The Future Isn’t in Molecules, It’s in Software 🛑 Here’s what nobody wants to admit in biotech: While everyone’s chasing the next miracle drug or genetic breakthrough, the real innovation is being ignored. 💡 At CytoCync, we’re calling it like it is: Biotech’s biggest opportunity isn’t in some new molecule. It’s in software that actually works. 🧬 Think about it: We pour billions into drug discovery, but companies still run on archaic systems that slow down development and stifle breakthroughs. The problem isn’t the science; it’s the infrastructure. 🚀 Biotech is decades behind. What other industry takes years to get from point A to point B? Tech moves in days, and biotech is stuck on pause. Here’s the kicker: Biotech leaders will spend millions on clinical trials but won’t invest a fraction of that in fixing the operational chaos. **Data silos, fragmented workflows, endless bureaucracy—**this is the unsexy stuff slowing down real innovation. 💬 Want to disrupt biotech? Start with the foundation. Let’s stop pretending a new molecule is the answer to everything. The future of biotech is software-first. #Biotech #HealthTech #UnpopularOpinion #DisruptBiotech #CytoCync #SoftwareOverScience

🔥 𝗨𝗻𝗹𝗼𝗰𝗸 𝘁𝗵𝗲 𝗸𝗲𝘆 𝘁𝗼 𝘄𝗶𝗻𝗻𝗶𝗻𝗴 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿𝘀! 🔥 Top tips from expert Dr. Rebekka Müller!💡 After the summer break is before the next event! We are excitedly looking forward to our next Check-in – it will be the very first event for the Batch #4 teams in Phase 1 after the Bootcamp. In order to properly kick off Phase 1 of the MAX!mize incubator for Max Planck start-ups, which is centred around the #validation and #exploration of the #startup idea for 6 months, there are many valuable #workshops on the agenda. To get things started here and now, we would like to introduce you to Dr. Rebekka Müller. Together with the teams, she will take a closer look at the topics of #CustomerDefinition & #ValueProposition. 🚀 As technology scout at Ascenion GmbH, Rebekka is working together with founders, inventors and scientists from research institutions and university hospitals, helping them advance their projects towards application. She combines deep industry and market experience from her previous marketing roles at Sanofi with profound scientific expertise, holding a PhD in molecular medicine. We interviewed Rebekka in advance and asked her the following question: 𝗜𝗻 𝘆𝗼𝘂𝗿 𝗼𝗽𝗶𝗻𝗶𝗼𝗻, 𝘄𝗵𝗮𝘁 𝗮𝗿𝗲 𝘁𝗵𝗲 𝘁𝗵𝗿𝗲𝗲 𝗺𝗼𝘀𝘁 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗳𝗮𝗰𝘁𝗼𝗿𝘀 𝘁𝗵𝗮𝘁 𝗻𝗲𝗲𝗱 𝘁𝗼 𝗯𝗲 𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗲𝗱 𝘄𝗶𝘁𝗵 𝗿𝗲𝗴𝗮𝗿𝗱 𝘁𝗼 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿 𝗱𝗲𝗳𝗶𝗻𝗶𝘁𝗶𝗼𝗻 & 𝘃𝗮𝗹𝘂𝗲 𝗽𝗿𝗼𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻? ⬇️ You can find her answer in the slideshow. Would you have expected this?

Very exited to invest in #Neurable via Jolt VC. While the spotlight is on #Neuralink, neurological competitors are emerging. "Led by CEO Dr. Ramses Alcaide, Neurable is a neurotechnology company that specializes in the development of AI-powered tools for brain signal translation and brain-computer interface technology. Empowered by patented signal processing, developed through research across labs and institutions, and advanced by a scientific and expert product team, its platform enables high-performance brain-computer interface in everyday devices. With over $30m raised since its founding, the company is working with its licensing partnership network to make neurotechnology a reality, including through the upcoming launch of the Neurable AI-powered MW75 Neuro headphones. Also following Series A, Neurable partnered with Air Force Research Lab’s 711 Human-Performance Wing to validate its technology and explore how it could be used to improve human performance. Building on this collaboration, the company secured $5M in contracts from the Department of Defense to further develop this human technology to support soldier health and performance." https://lnkd.in/grU4ahKf Want access to deals like this? Join my syndicate and invest while the tide is out: https://lnkd.in/gqBw3WhK